Stenosis (SAMMPRIS) trial demonstrated superiority of aggressive medical management over stenting.
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the impact of baseline characteristics on the differences in outcome.
Methods

Qualifying Criteria and Outcome
The qualifying criteria for the two studies have been published in detail previously. 2, 4 Because WASID enrolled patients with a broader range of stenosis (50%-99% versus 70%-99% in SAMMPRIS) and a longer qualifying period from the last symptomatic stroke or TIA to enrollment (90 days versus 30 days in SAMMPRIS), the entire population of WASID was not comparable to that in SAMMPRIS. Therefore, for this analysis, we compared all 227 patients randomized to the medical arm of SAMMPRIS with the 143 patients in WASID who met the following primary SAMMPRIS-qualifying criteria: 70% to 99% stenosis determined by the local investigator, <81 years old, absence of tandem stenoses, and ≤30 days from qualifying event to randomization. The outcome for this analysis was the SAMMPRIS primary end point: any stroke or death within 30 days after enrollment or ischemic stroke in the territory of the qualifying artery beyond 30 days of enrollment.
Statistical Methods
An unadjusted comparison of the SAMMPRIS primary end point between the 2 studies was made by estimating the cumulative probability of the outcome versus time for each study using the Kaplan-Meier method, with the resulting curves compared between the studies using the log-rank test. Although we included in the analysis only the WASID patients who met the primary eligibility criteria that differed between WASID and SAMMPRIS, there could have been differences between the 2 selected study populations in terms of the baseline characteristics that were related to the outcome. We used the following process to identify and adjust the comparison of the studies for such confounding factors. Baseline characteristics were compared between the 2 studies using Fisher exact test for percentages, t test for means, and the Wilcoxon rank-sum test for medians. Also, the relationship of each of the baseline characteristics (other than the study participated in) to the outcome was assessed using bivariate and multivariable proportional hazards regression in the set of patients formed by combining the 2 studies. We identified the baseline characteristics that were both significantly different between the studies and also significantly associated with the outcome. A proportional hazards regression model was fit that included terms for the baseline characteristics identified and also a term for the study that was participated in. The hazard ratio comparing the 2 studies was estimated from that model. To further adjust for any potential confounding factors, the baseline characteristics that were statistically different between the studies and not already in the model were added one at a time to the model and were retained in the model if the hazard ratio comparing the studies changed by >10% from the hazard ratio estimated without the newly added characteristic. If a characteristic to be added had missing data, then the hazard ratios to be compared were estimated from the same set of patients. All analyses were done using SAS 9.3. All reported P values are 2-sided, and those <0.05 are considered statistically significant.
Results
Unadjusted Comparison of Outcome Between Studies
The Kaplan-Meier curves for the risk of the SAMMPRIS primary end point were significantly different between WASID and SAMMPRIS ( Figure, Table 1 , P=0.009). WASID patients had greater risk of the outcome at 1, 2, and 3 years after enrollment (21.9%, 23.7%, and 28.9%, respectively) compared with SAMMPRIS patients (12.6%, 14.1%, and 14.9%, respectively). The unadjusted hazard ratio (WASID relative to SAMMPRIS) was 1.9 (95% confidence interval =1.2-3.0). (39 versus 44 mg/dL; P=0.0004). There were no significant differences in the frequency of female sex, black race, stroke as the qualifying event, diabetes mellitus, smoking, physical activity, history of previous stroke, time from qualifying event to study entry, history of coronary artery disease, stroke scale scores, or HgbA1c among patients with a history of diabetes mellitus ( Table 2) .
Comparison of Baseline Characteristics Between Studies
Association of Baseline Characteristics and Outcome
In bivariate analyses, the following baseline characteristics were found to be significantly related to outcome in the combined set of WASID and SAMMPRIS patients (Table 3) : female sex, history of diabetes mellitus, not using statin at enrollment, modified Rankin score ≥1, National Institute of Health stroke scale score ≥1, old infarcts in the territory of the symptomatic artery, and stroke as the qualifying event all conferred a significantly higher risk of the SAMMPRIS primary end point.
The baseline characteristics that were both different between the studies and related to outcome and thus potential confounders were no statin use at enrollment (more prevalent among WASID patients) and old infarcts in the territory of the symptomatic artery (more prevalent among SAMMPRIS patients). In a multivariable analysis, both characteristics were found to be related to the outcome with the following hazard ratios-no statin use at enrollment: 2.0 (95% confidence interval =1.1-3.3, P=0.019), old infarcts in the territory of the symptomatic artery 1.9 (95% confidence interval =1.1-2.9, P=0.019).
Adjusted Comparison of Outcome Between Studies
When adjusted for no statin use at enrollment and old infarcts in the territory of the symptomatic artery, the estimated hazard ratio for WASID versus SAMMPRIS was 1.9 (95% confidence interval =1.1-3.2, P=0.016), demonstrating a higher risk of the outcome among WASID patients (Table 4 ). To determine whether there were additional confounding factors, the baseline characteristics other than no statin use at enrollment and old infarcts in the territory of the symptomatic artery that were significantly different between the studies (Table 2) : age, history of hypertension, symptomatic artery, percent stenosis, systolic and diastolic blood pressure, body mass index, lowdensity lipoprotein, and high-density lipoprotein were individually added to the model, and the effect on the hazard ratio was noted. None of those factors changed the hazard ratio by >10%. The percent change ranged from 0.8% to 7.8%.
Discussion
The 1, 2, and 3-year rates of the primary end point were 42%, 41%, and 48% lower, respectively, in SAMMPRIS medically treated patients compared with WASID patients who met the SAMMPRIS entrance criteria. Our analysis sought to explore whether SAMMPRIS patients had a lower rate of major vascular events because of a lower burden of vascular risk factors compared with WASID patients.
SAMMPRIS patients were younger, had lower low-density lipoprotein at baseline (because of higher statin use), and had a higher frequency of anterior circulation stenosis. Younger age and lower cholesterol have been associated with a lower risk of stroke in patients with intracranial stenosis 5, 6 ; however, WASID showed no increased risk of stroke with posterior circulation stenosis in medically treated patients. 7 On the other hand, SAMMPRIS patients had higher frequencies of hypertension, mean systolic blood pressure, mean body mass index, more severe stenosis (80%-99%), and old infarct in the territory of the symptomatic artery. Raised systolic blood pressure and severe stenosis were strongly associated with an increased risk of stroke in patients with intracranial stenosis in WASID. [6] [7] [8] Among the baseline characteristics evaluated, we identified lack of statin use at baseline and old infarcts in the territory of the stenotic artery as confounding factors in that they were significantly different in frequency between WASID and SAMMPRIS patients and were associated with a worse outcome. After adjusting for these factors, WASID patients were still at a 2-fold higher risk of the primary end point. This result supports the hypothesis that the lower risk of the primary end point in SAMMPRIS patients is as a result of the differences in medical management between the 2 studies.
In addition to differences in risk factor control, changes in antithrombotic therapy between the 2 studies may have played a role. The SAMMPRIS regimen utilized dual antiplatelet therapy with aspirin and clopidogrel for 90 days compared with either aspirin monotherapy or warfarin in WASID. Dual antiplatelet therapy has been shown to reduce stroke in patients with recent minor stroke or transient ischemic attack in the Clopidogrel in High-Risk patients with Acute Nondisabling Cerebrovascular Events trial. 9 In addition, a recent meta-analysis found that when treatment was initiated within 3 days of the index TIA or stroke, dual antiplatelet therapy reduced the risk of stroke by 31% compared with antiplatelet monotherapy. 10 This study has some limitations. The increased frequency of hypertension in SAMMPRIS might reflect changes in the JNC definition of hypertension after the start of WASID. 11 However, this is an unlikely explanation given that SAMMPRIS patients had significantly higher systolic blood pressure at baseline compared with WASID patients. In addition, the studies were done in different time periods, and other variations in secular treatment patterns during the course of these 2 trials may have existed, which could explain some of the differences in event rates in these 2 trials. 12 In conclusion, compared with WASID patients who met the SAMMPRIS qualifying criteria, SAMMPRIS patients were slightly younger but had a higher burden of other poor prognostic features. Analyses comparing the SAMMPRIS primary *Comparisons of the baseline characteristics of the 2 studies were made using either an independent groups t test (for means), Fisher exact test (for percentages), or the Wilcoxon rank-sum test (for medians).
†Physical activity was measured in the 2 studies as follows: SAMMPRIS used the Physician-based Assessment and Counseling for Exercise (PACE) Current Physical Activity Status Score with a score of 1-3 considered in target. WASID used 4 categories (sedentary, minimal, moderate, vigorous) with moderate or vigorous considered in target.
‡Percent stenosis according to the reading of the angiogram by the study physician at the patient's clinical site.
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